Up-regulation of prolactin gene expression and feedback modulation of lymphocyte proliferation during acute allograft rejection

Gary K. Shen, David W Montgomery, Ellen D. Ulrich, Kevin R. Mahoney, Charles F. Zukoski

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background. Although recent evidence suggests that prolactin is important in the immune response, bidirectional communication between prolactin and the immune system has not been demonstrated previously. We examined our hypothesis that this communication exists during mouse skin allograft rejection. Methods. Serum prolactin levels were measured by bioassay, and pituitary prolactin mRNA was examined by use of Northern blots, in BALB/c mice receiving skin allografts from C57BL mice, on days 2, 4, and 6 after grafting. The feedback effects of prolactin on splenic lymphocytes were assessed in one-way mixed lymphocyte reactions, with or without added interleukin-2 (IL-2) or IL-4. Results. Prolactin mRNA was increased significantly in grafted animals compared with sham animals (2.4-fold by day 4). Serum prolactin bioactivity was also elevated on all days tested. Prolactin treatment resulted in dose-dependent modulation of the mixed lymphocyte reaction with lymphocytes from grafted animals but not from sham animals. These effects depended on the time points and the presence of IL-2 or IL-4; the maximal enhancement occurred with day-4 lymphocytes cultured with IL-4 (80%). Conclusions. This report is the first to implicate in vivo immune regulation of prolactin gene expression. Our observations indicate that bidirectional interaction exists between prolactin and the immune system and provide a rationale for altering prolactin levels to treat allograft rejection.

Original languageEnglish (US)
Pages (from-to)387-394
Number of pages8
JournalSurgery
Volume112
Issue number2
StatePublished - 1992

Fingerprint

Gene Expression Regulation
Prolactin
Allografts
Up-Regulation
Lymphocytes
Interleukin-4
Mixed Lymphocyte Culture Test
Interleukin-2
Immune System
Rejection (Psychology)
Messenger RNA
Skin
Serum
Inbred C57BL Mouse
Biological Assay
Northern Blotting
Communication

ASJC Scopus subject areas

  • Surgery

Cite this

Up-regulation of prolactin gene expression and feedback modulation of lymphocyte proliferation during acute allograft rejection. / Shen, Gary K.; Montgomery, David W; Ulrich, Ellen D.; Mahoney, Kevin R.; Zukoski, Charles F.

In: Surgery, Vol. 112, No. 2, 1992, p. 387-394.

Research output: Contribution to journalArticle

Shen, Gary K. ; Montgomery, David W ; Ulrich, Ellen D. ; Mahoney, Kevin R. ; Zukoski, Charles F. / Up-regulation of prolactin gene expression and feedback modulation of lymphocyte proliferation during acute allograft rejection. In: Surgery. 1992 ; Vol. 112, No. 2. pp. 387-394.
@article{17bc0b3ee73c425eaf91c412586152c3,
title = "Up-regulation of prolactin gene expression and feedback modulation of lymphocyte proliferation during acute allograft rejection",
abstract = "Background. Although recent evidence suggests that prolactin is important in the immune response, bidirectional communication between prolactin and the immune system has not been demonstrated previously. We examined our hypothesis that this communication exists during mouse skin allograft rejection. Methods. Serum prolactin levels were measured by bioassay, and pituitary prolactin mRNA was examined by use of Northern blots, in BALB/c mice receiving skin allografts from C57BL mice, on days 2, 4, and 6 after grafting. The feedback effects of prolactin on splenic lymphocytes were assessed in one-way mixed lymphocyte reactions, with or without added interleukin-2 (IL-2) or IL-4. Results. Prolactin mRNA was increased significantly in grafted animals compared with sham animals (2.4-fold by day 4). Serum prolactin bioactivity was also elevated on all days tested. Prolactin treatment resulted in dose-dependent modulation of the mixed lymphocyte reaction with lymphocytes from grafted animals but not from sham animals. These effects depended on the time points and the presence of IL-2 or IL-4; the maximal enhancement occurred with day-4 lymphocytes cultured with IL-4 (80{\%}). Conclusions. This report is the first to implicate in vivo immune regulation of prolactin gene expression. Our observations indicate that bidirectional interaction exists between prolactin and the immune system and provide a rationale for altering prolactin levels to treat allograft rejection.",
author = "Shen, {Gary K.} and Montgomery, {David W} and Ulrich, {Ellen D.} and Mahoney, {Kevin R.} and Zukoski, {Charles F.}",
year = "1992",
language = "English (US)",
volume = "112",
pages = "387--394",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Up-regulation of prolactin gene expression and feedback modulation of lymphocyte proliferation during acute allograft rejection

AU - Shen, Gary K.

AU - Montgomery, David W

AU - Ulrich, Ellen D.

AU - Mahoney, Kevin R.

AU - Zukoski, Charles F.

PY - 1992

Y1 - 1992

N2 - Background. Although recent evidence suggests that prolactin is important in the immune response, bidirectional communication between prolactin and the immune system has not been demonstrated previously. We examined our hypothesis that this communication exists during mouse skin allograft rejection. Methods. Serum prolactin levels were measured by bioassay, and pituitary prolactin mRNA was examined by use of Northern blots, in BALB/c mice receiving skin allografts from C57BL mice, on days 2, 4, and 6 after grafting. The feedback effects of prolactin on splenic lymphocytes were assessed in one-way mixed lymphocyte reactions, with or without added interleukin-2 (IL-2) or IL-4. Results. Prolactin mRNA was increased significantly in grafted animals compared with sham animals (2.4-fold by day 4). Serum prolactin bioactivity was also elevated on all days tested. Prolactin treatment resulted in dose-dependent modulation of the mixed lymphocyte reaction with lymphocytes from grafted animals but not from sham animals. These effects depended on the time points and the presence of IL-2 or IL-4; the maximal enhancement occurred with day-4 lymphocytes cultured with IL-4 (80%). Conclusions. This report is the first to implicate in vivo immune regulation of prolactin gene expression. Our observations indicate that bidirectional interaction exists between prolactin and the immune system and provide a rationale for altering prolactin levels to treat allograft rejection.

AB - Background. Although recent evidence suggests that prolactin is important in the immune response, bidirectional communication between prolactin and the immune system has not been demonstrated previously. We examined our hypothesis that this communication exists during mouse skin allograft rejection. Methods. Serum prolactin levels were measured by bioassay, and pituitary prolactin mRNA was examined by use of Northern blots, in BALB/c mice receiving skin allografts from C57BL mice, on days 2, 4, and 6 after grafting. The feedback effects of prolactin on splenic lymphocytes were assessed in one-way mixed lymphocyte reactions, with or without added interleukin-2 (IL-2) or IL-4. Results. Prolactin mRNA was increased significantly in grafted animals compared with sham animals (2.4-fold by day 4). Serum prolactin bioactivity was also elevated on all days tested. Prolactin treatment resulted in dose-dependent modulation of the mixed lymphocyte reaction with lymphocytes from grafted animals but not from sham animals. These effects depended on the time points and the presence of IL-2 or IL-4; the maximal enhancement occurred with day-4 lymphocytes cultured with IL-4 (80%). Conclusions. This report is the first to implicate in vivo immune regulation of prolactin gene expression. Our observations indicate that bidirectional interaction exists between prolactin and the immune system and provide a rationale for altering prolactin levels to treat allograft rejection.

UR - http://www.scopus.com/inward/record.url?scp=0026645932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026645932&partnerID=8YFLogxK

M3 - Article

C2 - 1386479

AN - SCOPUS:0026645932

VL - 112

SP - 387

EP - 394

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -